お知らせ • Apr 21
Epigenomics AG, Annual General Meeting, May 27, 2026 Epigenomics AG, Annual General Meeting, May 27, 2026, at 09:00 W. Europe Standard Time. お知らせ • Apr 03
Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026 Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026 お知らせ • Jul 17
Epigenomics AG, Annual General Meeting, Aug 27, 2025 Epigenomics AG, Annual General Meeting, Aug 27, 2025, at 10:30 W. Europe Standard Time. お知らせ • Oct 12
New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million. New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG for $9.8 million on July 24, 2023. Under the terms of consideration, As consideration for the sale, Epigenomics AG will receive a purchase price of up to USD 12.05 million, which can be broken down as follows: Cash payments of USD 1.8 million: USD 0.5 million on the closing date, USD 1.0 million on December 1, 2023 and USD 0.3 million on June 30, 2024. Further cash payments of up to USD 8.0 million contingent on the achievement of certain milestones related to Epi proColon and foremost Epi proColon “Next-Gen”. An interest in the acquirer of 3.0%, valued at least at USD 2.25 million. In addition, the Company will receive royalty or earn-out payments, in the form of royalties linked to the commercialization of the “Next-Gen”-Test. These payments extend probably until October 2043, the year in which patent protection for the product is expected to expire. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property along with all patents as well as the entire biobank, and thus all of its assets within the meaning of Section 179a of the German Stock Corporation Act (AktG), to the acquirer. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer. The agreement is subject to certain closing conditions, including the approval at the Company’s Extraordinary General Meeting. The sale of the assets to New Day Diagnostics is expected to enable the commercialization of Epi proColon “Next-Gen” and secure future cash flows for Epigenomics AG. As of September 14, 2023, Extraordinary General Meeting of Epigenomics approved the transaction. The closing of the agreement remains subject to customary closing conditions, and both parties are diligently working towards its completion.
TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors.
New Day Diagnostics, LLC completed the acquisition of Substantially all of Assets of Epigenomics AG on October 10, 2023. お知らせ • Jul 26
New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG. New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG on July 24, 2023. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors. お知らせ • Jun 13
Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5m Epigenomics AG (XTRA:ECX1) shares more than doubled in value on June 12, 2023 after it said it is holding talks with an unidentified U.S. company to sell nearly all of its assets for around $11.5 million. The German medical diagnostic company said the potential deal, which is unbinding and therefore could still fail, relates to the patents and other rights of its blood tests to screen for colon cancer and all blood samples owned by Epigenomics. Current negotiations place the deal closing in December, Epigenomics said. The unidentified acquirer would also have to pay royalties and other costs associated with the potential commercialization of a diagnostic test in development. お知らせ • May 20
Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023 Epigenomics AG announced that Member of the Executive Board, President, and Chief Scientific Officer Dr. Andrew Lukowiak, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective May 31, 2023. Between now and the resignation date Dr. Lukowiak will continue to support the Company’s restructuring efforts in coordination with the Supervisory Board. The Company continues to be committed to maximizing the value of its technology through corporate partnering, licensing and/or asset sales. Dr. Lukowiak has been a Member of the Executive Board, President, and CSO of Epigenomics AG since December 2021. His broad contributions across the organization have been instrumental in furthering the Company’s colorectal cancer diagnostics’ program, including his systematic optimization of R&D structure and processes, as well as his execution of complementary partnerships. However, in recent months, in the current capital market environment, the Company has been unable to raise additional capital to secure funding for the FDA pivotal study of the "Next-Gen" test. In response, the restructuring of the Company was initiated on February 15, 2023 to minimize costs. Against this backdrop, the resignation of Dr. Andrew Lukowiak now also takes place.